Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development

Medicinal Research Reviews

Volumn 32, Issue 6, 2012, Pages 1197-1219

  Shashidharamurthy, Rangaiah ^a   Bozeman, Erica N ^a   Patel, Jaina ^a   Kaur, Ramneet ^a   Meganathan, Jeyandra ^a   Selvaraj, Periasamy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer immunotherapy; Cancer vaccine; Cytokines; Glycosylphosphatidylinositol (GPI); Immunostimulatory molecules; Protein transfer

Indexed keywords

ALEMTUZUMAB; ALPHA2A INTERFERON; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; DENDRITIC CELL VACCINE; DOCETAXEL; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IBRITUMOMAB TIUXETAN; INTERLEUKIN 15; INTERLEUKIN 2; MONOCLONAL ANTIBODY; OFATUMUMAB; PANITUMOMAB; PREDNISONE; RITUXIMAB; SIPULEUCEL T; THALIDOMIDE; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84867461170     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20237     Document Type: Article

References (170)

1. Rosenberg SA. Shedding light on immunotherapy for cancer. N Eng J Med. 2004;350:1461-1463.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
3. Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265-270.
4. Hellstrom KE, Hellstrom I. Principles of tumor immunity: Tumor antigens. In: De Vita VT, Hellman S, Rosenberg SA, editors. The biologic therapy of cancer. Philadelphia: J.B. Lippincott Co.; 1991. pp 35-52.
5. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: A costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445-480.
6. Johnson JG, Jenkins MK. Accessory cell-derived signals required for T cell activation. Immunol Res. 1993;12:48-64.
7. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today. 1993;14:483-486.
8. Lanier LL. Distribution and function of lymphocyte surface antigens. Molecules costimulating T lymphocyte activation and function. Ann NY Acad Sci. 1993;677:86-93.
9. Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol. 1990;170:3806-3811.
10. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
11. Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L. Costimulation of tumor reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994;153:421-428.
12. Smythe JA, Fink PD, Logan GJ, Lees J, Rowe J, Alexander IE. Human fibroblast transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: Implications for immune augmentation cancer therapy and autoimmunity. J Immunol. 1999;163:3239-3249.
13. Poloso N, Nagarajan S, Bumgarner GW, Selvaraj P. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine. 2001;19:2029-2038.
14. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
15. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li XF, Shimizu J, Fujiwara H, Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function: Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol. 1991;146:1077-1082.
16. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma. Int J Clin Oncol. 1994;56:755-760.
17. Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101:4878-4886.
18. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775-787.
19. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296.
20. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115-123.
21. Coe D, Begom S, Addey C, White M, Dyson J, Chai J. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother. 2010;59:1367-1377.
22. Krusch M, Baltz KM, Bringmann A, Brossart P, Salih HR. Tumor-derived soluble glucocorticoid-induced TNF-related protein (GITR) ligand diminishes antitumor reactivity of NK cells. FASEB J. 2008;22:1079.25-
23. Fujimura T, Mahnke K, Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci. 2010;59:1-6.
24. Song X, Krelin Y, Dvorkin T, Bjorkdahi O, Segal S, Dinarello CA, Voronov E, Apte RN. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1b-secreting cells. J Immunol. 2005;175:8200-8208.
25. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello R. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003;24:302-306.
26. Ochoa AC, Zea HA, Hernandex C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13:721s-725s.
27. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180-191.
28. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumor angiogenesis. Nat Rev Cancer. 2008;8:618-631.
29. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174.
30. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoid like stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010;328:697-698.
31. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR. Program death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced acute myeloid leukemia (AML). Blood. 2010;116:2484-2493.
32. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457-1464.
33. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101:2620-2627.
34. Hirahara N, Nio Y, Sasaki S, Minari Y, Takamura M, Iguchi C, Dong M, Yamasawa K, Tamura K. Inoculation of human interleukin-17 gene-transfected meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology. 2001;61:79-89.
35. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114:357-359.
36. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010;184:1630-1641.
37. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and Th17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2009;69:5522-5530.
38. Herlock C, Scott B, Dyson PJ, Morishita M, Coombes RC, Savage P, Stebbing J. The effects of trastuzumab on the CD4+ CD25+ FoxP3+ and CD4+ IL17+ T-cell axis in patients with breast cancer. Br J Cancer. 2009;100:1061-1067.
39. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 1999;50:507-529.
40. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245-273.
41. Rosenberg SA, Yang CJ, Restifo PN. Cancer immunotherapy: Moving beyond current vaccines. Nat Med. 2004;10:909-915.
42. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525-531.
43. Ridgeway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21:876-886.
44. Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines. Curr Opin Immunol. 2000;12:583-588.
45. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy M. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science. 1994;263:518-520.
46. Gong J, Chen D, Kashowaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic cells and carcinoma cells. Nat Med. 1997;3:558-561.
47. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: Mapping the way. Nat Med. 2004;10:475-480.
48. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinsk D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
49. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
50. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol. 2006;18:201-205.
51. Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G, Giesler JM, Juttner E, Peters JH, Haring B, Leo R, Unger C, Azemar M. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-A pilot study. Prostate. 2007;67:500-508.
52. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68:5955-5964.
53. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur SJ, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic SV. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphotase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate. 2004;60:197-204.
54. Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther. 2007;7:1275-1280.
55. Small EJ, Schellhammer PF, Higano CS, Neumanaitis J, Valone F, Hershberg R. Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC). ASCO. 2005;4500:Abstract.
56. Eaton JD, Perry MJ, Nicholson S, Guckian M, russell N, Whelan M, Kirby RS. Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer. BJU Int. 2002;89:19-
57. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines. 2005;4:259-274.
58. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010;20:241-246.
59. Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as post remission therapy for acute myeloid leukemia (AML). Blood. 2009;114:1736-1745.
60. Rosenberg SA, Lotze MT, Yang JC. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474-484.
61. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected state IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
62. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99:67-74.
63. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature. 2004;4:11-22.
64. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
65. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991;353:858-861.
66. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA. 2000;97:11445-11450.
67. Diab A, Cohen AD, Alpdogan O, Perales MA. IL-15: Targeting CD8+ T cells for immunotherapy. Cytotherapy. 2005;7:23-35.
68. Araki A, Hazama S, Yoshimura K, Yoshino S, Iizuka N, Oka M. Tumor secreting high levels of IL-15 induces specific immunity to low immunogenic colon adenocarcinoma. Int J Mol Med. 2004;14:571-576.
69. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA, Tagaya Y. IL-15 presentation in the activation of NK-mediated killing, which leads to enhanced tumor immunesurveillance. Blood. 2005;105:721-727.
70. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA. 2004;101:1969-1974.
71. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2 and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): An open-label randomized trial. Lancet. 2010;375:641-648.
72. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;16:3127-3132.
73. Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol. 1990;8:1650-1656.
74. Forni G, Musso T, Santoni A, Giovarelli M. Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth. Prog Clin Biol Res. 1987;244:105-
75. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57:503-512.
76. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. IL-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
77. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal caner by tumor cells engineered to secrete interleukin-4. Science. 1991;257:713-716.
78. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky HI, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
79. Ortiz-Sanchez E, Helguera G, Daniels TR, Penichet ML. Antibody-cytokine fusion proteins: Applications in cancer therapy. Expert Opin Biol Ther. 2008;8:609-632.
80. Burton ER, Libutti SK. Targeting TNFalpha for cancer therapy. J Biol. 2009;8:85.1-85.5.
81. Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK. Tumor vasculature-targeted delivery of tumor necrosis factor alpha. Cancer. 2009;115:128-139.
82. Amato RJ, Malya R, Rawat A. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. Am J Clin Oncol. 2008;31:237-243.
83. Lutzky J, Weber R, Nunez Y, Gillett M, Spitler L. A phase I study of granulocyte macrophage colony-stimulating factor (Sargramostim) and escalating doses of thalidomide in patients with high risk malignant melanoma. J Immunther. 2009;32:79-85.
84. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2:52-62.
85. Reichert JM, Valge-Archer V. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007;6:349-356.
86. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M. NK cells and cancer. J Immunol. 2007;178:4011-4016.
87. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science. 1983;221:865-867.
88. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038-1043.
89. Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol. 2008;632:159-174.
90. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
91. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant. 2006;6:859-866.
92. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, VanDenNeste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Eng J Med. 2002;346:235-242.
93. Osterborg A. Ofatumumab, a human anti-CD20 monoclonal antibody. Expert Opin Biol Ther. 2010;10:439-449.
94. Davies A. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene. 2007;26:3614-3628.
95. Jacene H, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and I31I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767-1776.
96. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. IDEC-C2B8 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
97. Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Level of CD20 expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43:149-151.
98. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 molecules. J Immunol. 2006;176:2600-2609.
99. Beers SA, French RR, Claude Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PWM, Sjef Verbeek S, Glennie MJ, Cragg MS. Antigenic modulation limits the efficacy of anti-CD20 antibodies: Implications for antibody selection. Blood. 2010;115:5191-5201.
100. Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res. 2002;8:2701-2713.
101. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarlian H, Giles F, Keating M, Albitar M. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102:3514-3520.
102. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62:873-882.
103. Xia MQ, Tone M, Packman L, Hale G, Waldmann H. Characterization of the CAMPATH-1(CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol. 1991;21:1677-1684.
104. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: Alemtuzumab as single agent treatment for B cell CLL. Oncologist. 2008;13:167-174.
105. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240:1198-1201.
106. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002;13:40-66.
107. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47-58.
108. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L, Sklarin N, Seidman A, Hudis C, Moore J, Rosen P, Twaddell T, Henderson L, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737-744.
109. Salmon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
110. Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Immunol. 2009;625:41-45.
111. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
112. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18:977-984.
113. Norton L, Slamon D, Leyland-Jones B. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 1999;127a.
114. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
115. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
116. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
117. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
118. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H, Maki RG. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005;23:7135-7142.
119. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
120. Mcdermott DF, George DJ. Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data. Cancer Treat Rev. 2010;36:216-223.
121. Messa C, Russo F, Caruso MG, DiLeo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998;37:285-289.
122. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
123. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
124. Lockhart C, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol. 2005;32:52-60.
125. Baselga J. The EGFR as a target for anticancer therapy-Focus on cetuximab. Eur J Cancer. 2001;37:S16-S22.
126. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23.
127. Morris JC, Waldmann TA. Antibody-based therapy of leukemia. Expert Rev Mol Med. 2009;11:1-25.
128. Kay MA, Woo SL. Gene therapy for metabolic disorders. Trends Genet. 1994;10:253-257.
129. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346-358.
130. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798-806.
131. Li S, Simmons J, Detorie N, O'Rourke B, Hamper U, DeWeese TL. Dosimetric and technical considerations for interstitial adenoviral gene therapy as applied to prostate cancer. Int J Radiat Oncol Biol Phys. 2003;55:204-214.
132. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, 3rd, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF. Phase II trial of intravenous Cl-1042 in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:1498-1504.
133. Verma IM, Somia N. Gene therapy-promises, problems and prospects. Nature (London). 1997;389:239-242.
134. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, Gansbacher B. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 1992;52:6229-6236.
135. Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, Gliboa E, Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood. 1992;80:2817-2825.
136. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, Von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C. Murine leukemia induced by retroviral gene marking. Science. 2002;296:497-
137. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-XI. Science. 2003;302:415-419.
138. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther. 2004;15:1157-1166.
139. Cross D, Burmester JK. Gene therapy for cancer treatment: Past, present and future. Clin Med Res. 2006;3:218-227.
140. Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Morishita R. Development of safe and efficient novel nonviral gene transfer using ultrasound: Enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 2002;9:372-380.
141. Wheeler CJ, Flegner PL, Tsai YJ, Marshall J, Sukhu L, Doh SG, Hartikka J, Nietupski J, Manthorpe M, Nichols M, Plewe M, Liang X, Norman J, Smith A, Cheng SH. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci USA. 1996;93:11454-11459.
142. Li S, Wu SP, Whitmore M, Loeffert EJ, Wng L, Watkins SC, Pitt BR, Huang L. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol. 1999;276:L796-L804.
143. McHugh RS, Ahmed SN, Wang Y-C, Sell KW, Selvaraj P. Construction, purification and functional reconstitution on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA. 1995;92:8059-8063.
144. Nagarajan S, Anderson M, Ahmed SN, Sell KW, Selvaraj P. Purification and optimization of functional reconstitution on the surface of leukemic cell lines of GPI-anchored Fcγreceptor III. J Immunol Methods. 1995;184:241-251.
145. McHugh RS, Ahmed SN, Wang Y-C, Sell KW, Selvaraj P. Construction, purification, and functional reconstitution on tumor cells of a glycolipid anchored B7-1 molecule: A novel alternative to gene transfection in human immunotherapy. Proc Am Assoc Cancer Res. 1995;36:494-
146. McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Protein transfer of glycosylphosphatidylinositol-B7-1 into tumor cell membranes: A novel approach to tumor immunotherapy. Cancer Res. 1999;59:2433-2437.
147. Bozeman EN, Shashidharamurthy R, Paulos SA, Palaniappan R, D'Souza M, Selvaraj P. Cancer vaccine development: Designing tumor cells for greater immunogenicity. Front Biosci. 2010;15:309-320.
148. Selvaraj P, Plunkett ML, Dustin ML, Sanders ME, Shaw S, Springer TA. The T-lymphocyte glycoprotein CD2 binds the cell surface ligand. Nature. 1987;326:400-403.
149. Selvaraj P, Dustin ML, Silber R, Low MG, Springer TA. Deficiency of lymphocyte function associated antigen-3 (LFA-3) in paroxysmal nocturnal hemoglobinuria: Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med. 1987;166:1011-1025.
150. Selvaraj P, Rosse WF, Silber R, Springer TA. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal hemoglobinuria. Nature. 1988;333:565-567.
151. Udenfriend S, Kodukula K. How glycosyl phosphatidylinositol-anchored membrane proteins are made. Annu Rev Biochem. 1995;64:563-591.
152. Fujita M, Kinoshita T. Structural remodeling of GPI anchors during biosynthesis and after attachment to proteins. FEBS Lett. 2010;584:1670-1677.
153. Low MG. Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors. Biochem J. 1987;244:1-13.
154. Cross GAM. Glycolipid anchoring of plasma membrane proteins. Annu Rev Cell Biol. 1990;6:1-39.
155. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: A complex membrane-anchoring structure for proteins. Biochemistry. 2008;47:6991-7000.
156. Tykocinski ML, Shu H-K, Ayers DJ, Walter EI, Getty RR, Groger RK, Hauer CA, Medof ME. Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3′ end sequence of decay-accelerating factor's mRNA. Proc Natl Acad Sci USA. 1988;85:3555-3559.
157. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984;160:1558-1563.
158. Nagarajan S, Selvaraj P. Reconstitution of CD16 expression on nucleated cells using purified CD16. FASEB J. 1991;5:A1718-
159. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol. 1995;155:5498-5505.
160. Wang YC, Zhu L, McHugh R, Graham SD, Jr., Hillyer C, Dillehay D, Sell KW, Selvaraj P. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation. J Immunother. 1996;19:1-8.
161. Nagarajan S, Selvaraj P. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res. 2002;62:2869-2874.
162. Bumgarner GW, Shashidharamurthy R, Nagarajan S, D'Souza MJ, Selvaraj P. Surface engineering of microparticles by novel protein transfer for targeted antigen/drug delivery. J Control Release. 2009;137:90-97.
163. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71:1093-1102.
164. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA. 1993;90:6586-6590.
165. Baskar S, Ostrand Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA. 1993;90:5687-5690.
166. Poloso NJ, Nagarajan S, Mejia-Oneta JM, Selvaraj P. GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Mol Immunol. 2002;38:803-816.
167. Westerman LE, Sund SC, Selvaraj P, Jensen PE. Induction of tumor-specific immunity in mice by immunization with reconstituted tumor membrane liposomes containing recombinant B7-2. J Immunother. 2000;23:456-463.
168. Billadeau DD. ITAMs versus ITIMs: Striking a balance during cell regulation. J Clin Invest. 2002;109:161-168.
169. Shashidharamurthy R, Panchanathan R, Fiske ED, Tien L, Selvaraj P. Melanoma cells expressing membrane-anchored IL-2 and IL-12 induce effective antitumor immunity in the presence or absence of B7-1 costimulation. FASEB J. 2008;22:1078.21-
170. Nagarajan S, Selvaraj P. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: A potential approach for local delivery of cytokines during vaccination. Vaccine. 2006;24:2264-2274.